News | Ablation Systems | August 02, 2018

Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter

IDE study will assess safety and effectiveness of Thermedical’s catheter ablation system for treatment of ventricular tachycardia

Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter

August 2, 2018 — Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for the Early Feasibility Study (EFS) of the company’s Durablate ablation catheter. The single-arm, observational study is designed to evaluate the safety and effectiveness of the Durablate catheter to treat ventricular tachycardia (VT), a leading cause of sudden cardiac death in the United States.

The target population consists of patients who have already been treated with medicine, have an implantable cardioverter defibrillator (ICD), and who have had a conventional ablation procedure to treat VT, yet all their treatments have failed. The study is scheduled to begin in 2018 at Mayo Clinic under the direction of Douglas L. Packer, M.D., professor of medicine, and at Loyola University of Chicago Stritch School of Medicine, under the direction of David Wilber, M.D., medical director of clinical electrophysiology.

Implantable cardioverter defibrillators (ICDs) are the current standard-of-care treatment for patients suffering from VT; however, this approach does not stop the progression of the disease or provide a cure. In addition, ICDs can be costly and painful, and may substantially reduce a patient’s quality of life. VT patients who have ICDs and recurrent VT may be treated today with conventional RF ablation, which is a lengthy procedure that has a success rate of approximately 50 percent.

Thermedical’s patented ablation technology uses heat to kill the damaged heart muscle cells that are causing VT. The heat is delivered by the Durablate catheter, which simultaneously injects a precise flow of hot saline together with controlled RF energy into the heart tissue. This combination is an advanced form of biological heat transport that is 20 times more effective than conventional RF ablation methods. Compared to conventional VT ablation catheters, Durablate can more accurately control the ablation size, and it can treat tissue that is deeper in the heart wall, which is where life-threatening arrhythmias (abnormal, rapid heart rhythm) that cause VT are often located.

For more information:

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init